Compensation and Remuneration - The total pre-tax compensation for the company's directors and senior management amounted to 1,131.48 million CNY[1]. - The board of directors reviewed and approved the remuneration scheme for directors and senior management for the 2022 fiscal year[6]. - The company distributed cash dividends of ¥33,587.92 million (including tax) during the reporting period, with cumulative cash dividends over the last three years reaching ¥81,671.68 million, representing 35.12% of the net profit in the same period[88]. Internal Controls and Audits - The company conducted an internal control audit, identifying key risk areas and providing corrective measures based on audit findings[17]. - The audit report on internal controls received a standard unqualified opinion, indicating no significant deficiencies in non-financial reporting[20]. - There were no significant defects reported in financial or non-financial internal controls during the reporting period[40]. - The company has not identified any risks during the supervisory activities of the supervisory board in the reporting period[8]. Environmental Compliance and Sustainability - The company reported a significant focus on environmental compliance, with no major environmental incidents occurring throughout the year[34]. - The company has implemented automatic, manual, and periodic monitoring for pollution control, ensuring compliance with national pollution monitoring platforms[32]. - The company has committed to continuous improvement in environmental risk management and has established emergency response measures for environmental incidents[34]. - The company has complied with various environmental protection laws and regulations, ensuring adherence to national standards[43]. - The company has maintained a focus on sustainable practices, aligning its operations with environmental protection initiatives[36]. Research and Development - The company has invested significantly in R&D and project construction to enhance its core competitiveness amid a challenging external environment[67]. - R&D expenses for the reporting period amounted to ¥53,291.97 million, reflecting a year-on-year increase of 10%[99]. - The company has established R&D centers in all three major business segments, with a total of 1,026 R&D personnel, including 46 PhDs and 220 Master's degree holders[104]. - The company emphasizes a continuous increase in R&D investment to enhance its research capabilities and innovation[104]. - The company has increased its R&D personnel by 16.72% from 879 in 2021 to 1,026 in 2022, with the proportion of R&D staff rising from 14.33% to 15.11%[203]. Financial Performance - The company's total revenue for 2022 reached ¥10,544,905,377.17, representing a year-on-year increase of 17.92% compared to ¥8,942,618,232.82 in 2021[93]. - Net profit attributable to shareholders for 2022 was ¥989,173,675.64, a 3.52% increase from ¥955,550,170.21 in 2021[139]. - The net cash flow from operating activities reached ¥1,326,107,316.20, a significant increase of 116.77% compared to ¥611,748,728.68 in 2021[139]. - Total assets at the end of 2022 amounted to ¥12,016,599,023.18, reflecting a 32.86% increase from ¥9,044,671,981.35 at the end of 2021[139]. - The company's basic earnings per share for 2022 was ¥0.8425, up 3.91% from ¥0.8108 in 2021[139]. Market and Business Operations - The company primarily engages in the production of pharmaceutical raw materials, CDMO services, and formulations, adhering to environmental protection laws and industry standards[23]. - The company has a global marketing network covering over 70 countries and regions, with domestic market presence in all provinces except Qinghai and Tibet[64]. - The company's CDMO business revenue was composed of 87% from foreign clients and 13% from domestic clients, with a significant growth in domestic revenue in 2022[70]. - The number of ongoing CDMO projects increased by 62% year-on-year to 524, with 298 projects in the R&D stage (up 108%) and 226 in the commercialization stage (up 26%)[70]. - The company has established a management structure that includes three business divisions: API, CDMO, and FDF, aimed at enhancing operational efficiency[176]. Corporate Governance - The company has developed a self-assessment process for corporate governance, enhancing transparency and accountability[42]. - The company has actively engaged with stakeholders, including shareholders and suppliers, to align business practices with their interests[36]. - The company held its 2021 annual general meeting with a participation rate of 58.13% on March 31, 2022, and disclosed the resolutions on April 1, 2022[198]. - The company conducted its first extraordinary general meeting of 2022 with a participation rate of 54.82% on December 27, 2022, with resolutions disclosed on December 28, 2022[198].

创业板风险提示：本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产 业融合存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点， 投资者面临较大的市场风险。投资者应充分了解创业板市场的投资风险及本公司所披露 的风险因素，审慎作出投资决定。 山东科源制药股份有限公司 Shandong Keyuan Pharmaceutical Co.,Ltd. （住所：山东济南市山东商河经济开发区科源街） 首次公开发行股票并在创业板上市 招股说明书 （注册稿） 本招股说明书（申报稿）不具有据以发行股票的法律效力，仅供预先披露之用。投资 者应当以正式公告的招股说明书全文作为投资决定的依据。 保荐机构（主承销商） （住所：北京市朝阳区安立路 66 号 4 号楼） 山东科源制药股份有限公司 首次公开发行股票并在创业板上市招股说明书 1-1-1 免责声明：本公司的发行申请尚未经深圳证券交易所及中国证监会履行相应的程序。 山东科源制药股份有限公司 首次公开发行股票并在创业板上市招股说明书 发行概况 | 发行股票类型 | 人民币普通股（A股） | | --- | --- | | 发行股数 | 本次拟公开发行股票1 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥2,565,126,389.01, representing a year-over-year increase of 20.88%[3] - Net profit attributable to shareholders for Q3 2022 was ¥220,292,993.64, up 5.54% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥244,796,455.99, showing a significant increase of 44.21% year-over-year[3] - Total operating revenue for Q3 2022 reached ¥7,550,804,383.47, an increase of 17.98% compared to ¥6,399,153,386.70 in the same period last year[13] - Net profit for Q3 2022 was ¥657,091,282.69, a decrease of 13.81% from ¥762,133,599.43 in Q3 2021[14] - Total profit for Q3 2022 was ¥765,962,199.28, down 14.85% from ¥899,545,208.98 in the same quarter last year[14] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥11,157,718,538.84, reflecting a growth of 21.76% from the end of the previous year[3] - As of September 30, 2022, the total assets of the company reached CNY 11.16 billion, an increase from CNY 9.16 billion at the beginning of the year, representing a growth of approximately 21.8%[11] - The company's total liabilities increased, with short-term borrowings rising by 69.18% to ¥562,490,104.30 compared to the previous year[6] - The total liabilities of the company were CNY 5.97 billion, compared to CNY 4.10 billion at the beginning of the year, marking an increase of around 45.5%[12] Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥870,772,728.39, an increase of 31.74% compared to the same period last year[6] - Cash inflow from operating activities totaled ¥6,008,821,887.45, an increase of 19.5% from ¥5,029,206,843.86 year-on-year[15] - The net increase in cash and cash equivalents for the quarter was ¥357,478,983.53, compared to ¥49,549,859.45 in the same quarter last year[16] - The ending balance of cash and cash equivalents reached ¥2,156,631,616.93, up from ¥1,973,988,633.38 at the end of the previous period[16] Research and Development - Research and development expenses for the first nine months of 2022 were ¥405,006,874.25, which is a 25.98% increase year-over-year[6] - Research and development expenses rose to ¥405,006,874.25, representing a 25.94% increase from ¥321,495,631.04 in the previous year[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 58,851, with the largest shareholder holding 28.08% of the shares[7] Operational Efficiency and Future Plans - The company has plans for market expansion and new product development, although specific details were not provided in the report[12] - The report indicates a focus on enhancing operational efficiency and exploring strategic partnerships to drive future growth[12] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 4.24%, a decrease of 0.18% compared to the previous year[3] - Earnings per share (EPS) for Q3 2022 was ¥0.5594, down from ¥0.6467 in Q3 2021, reflecting a decrease of 13.46%[14] - The company reported a decrease in other comprehensive income, with a net amount of -¥1,369,975.63 compared to ¥37,930.80 in the previous year[14]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥4,985,677,994.46, representing a 16.57% increase compared to ¥4,277,125,693.79 in the same period last year[11]. - Net profit attributable to shareholders was ¥436,984,822.35, a decrease of 21.04% from ¥553,408,494.47 in the previous year[11]. - The basic earnings per share decreased by 20.98% to ¥0.3711 from ¥0.4696 in the same period last year[11]. - Total assets increased by 12.77% to ¥10,333,214,784.46 compared to ¥9,163,329,850.05 at the end of the previous year[11]. - The net assets attributable to shareholders decreased by 1.34% to ¥4,992,417,721.43 from ¥5,060,005,493.00 at the end of the previous year[11]. - The company reported a net cash flow from operating activities of ¥328,376,803.05, a slight increase of 1.61% from ¥323,169,178.27 in the previous year[11]. - The weighted average return on equity was 8.59%, down from 12.10% in the same period last year, reflecting a decrease of 3.51%[11]. - The company's operating costs increased by 25.44% to approximately CNY 3.74 billion, primarily due to rising raw material prices and increased freight costs[37]. Revenue Breakdown - The pharmaceutical main business generated ¥4,956,591,096.01, accounting for 99.42% of total revenue, with a year-on-year growth of 16.35%[39]. - Contract research services revenue increased by 27.79% to ¥921,144,358.77, representing 18.48% of total revenue[38]. - Domestic revenue was ¥2,836,934,879.85, a slight increase of 1.95% year-on-year, while international revenue surged by 43.77% to ¥2,148,743,114.61[38]. Research and Development - The company invested CNY 282 million in R&D, a 37.43% increase year-on-year, representing 5.66% of total revenue, with 933 R&D personnel including 45 PhDs and 207 Masters[22]. - The company has 13 products that have passed consistency evaluation, including three new formulations approved in the reporting period[21]. - The company holds a total of 138 valid patents, including 120 invention patents, with 12 new invention patent applications submitted during the reporting period[24]. Operational Efficiency - A total of 18 production lines underwent continuous transformation, and over 40 production lines were automated, significantly improving operational efficiency[26]. - The company completed 4,654 employee suggestions, 159 improvement projects, and 149 innovation projects, enhancing operational efficiency and reducing costs[28]. Environmental and Social Responsibility - The company has implemented ISO14001 and ISO45001 management systems to enhance environmental and occupational health safety standards[48]. - The company has a focus on environmental protection and has established a comprehensive EHS management system[48]. - The company actively engages in social responsibility initiatives, including community support and employee welfare programs[66]. Shareholder and Equity Information - The company plans to repurchase shares with a total fund of 200 million to 400 million yuan, having already repurchased 7,568,216 shares, accounting for 0.64% of the total share capital[31]. - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of the shares, totaling 330,941,729 shares[90]. - The total number of ordinary shareholders at the end of the reporting period was 59,683[90]. Risk Management - The company has identified potential risks in future operations and has outlined corresponding countermeasures in the management discussion section[2]. - The company is actively monitoring foreign exchange rate fluctuations to mitigate potential impacts on revenue from export operations[48]. Compliance and Governance - The company has received multiple certifications, including NMPA, FDA, and EU EDQM, ensuring compliance with international quality standards[34]. - There were no administrative penalties due to environmental issues during the reporting period[63]. - The company has not experienced any major litigation or arbitration matters during the reporting period[68]. Financial Position - Cash and cash equivalents at the end of the reporting period amounted to ¥2,672,534,937.85, accounting for 25.86% of total assets, a decrease of 2.62% from the previous year[40]. - The company reported a total of 205,313,446.13 in tax refunds received during the first half of 2022, compared to 161,923,834.61 in the same period of 2021[108]. - The total actual guarantee amount accounts for 65.66% of the company's net assets[85].

Financial Performance - The company's revenue for Q1 2022 was ¥2,101,428,825.31, representing a 6.85% increase compared to ¥1,966,705,576.05 in the same period last year[2] - Net profit attributable to shareholders decreased by 29.96% to ¥152,091,656.06 from ¥217,157,530.74 year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥135,904,532.94, down 28.30% from ¥189,535,650.14 in the previous year[2] - Total operating revenue for the first quarter of 2022 was CNY 2,101,428,825.31, an increase of 6.84% compared to CNY 1,966,705,576.05 in the same period last year[12] - Net profit for the first quarter of 2022 was CNY 152,091,656.06, a decrease of 30.03% from CNY 217,157,530.74 in the previous year[12] - Basic earnings per share for the first quarter of 2022 were CNY 0.1291, down from CNY 0.1843 in the same period last year, a decrease of 30%[14] Cash Flow - Operating cash flow increased by 15.89% to ¥171,696,287.82 compared to ¥148,153,167.43 in the same period last year[2] - The net cash flow from operating activities for Q1 2022 was ¥171,696,287.82, an increase from ¥148,153,167.43 in Q1 2021, representing a growth of approximately 15.4%[16] - Total cash inflow from operating activities amounted to ¥1,512,778,824.01, compared to ¥1,396,429,403.54 in the previous year, indicating an increase of about 8.3%[16] - Cash outflow from operating activities totaled ¥1,341,082,536.19, up from ¥1,248,276,236.11, reflecting a rise of approximately 7.4%[16] - The net cash flow from investing activities was -¥213,369,394.57, worsening from -¥25,016,560.53 year-over-year[16] - The net cash flow from financing activities increased by 78.80% to ¥363,036,069.47 from ¥203,041,368.36 year-on-year[5] - Cash inflow from financing activities reached ¥533,000,000.00, compared to ¥435,000,000.00 in the same quarter last year, marking an increase of about 22.5%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,019,157,968.42, a 9.34% increase from ¥9,163,329,850.05 at the end of the previous year[2] - The total liabilities increased to CNY 4,807,046,042.98 from CNY 4,103,324,357.05, representing a rise of 17.14%[11] - The company's total current assets as of March 31, 2022, amount to ¥6,521,432,245.87, an increase from ¥5,781,909,915.75 at the beginning of the year[9] - Cash and cash equivalents increased to ¥2,988,413,275.38 from ¥2,610,010,623.44[8] - Inventory as of March 31, 2022, is valued at ¥1,356,152,503.90, up from ¥1,249,878,604.74[9] - The company reported short-term borrowings of ¥501,225,701.15, an increase from ¥332,474,393.04[9] - Accounts payable decreased slightly to ¥1,237,962,676.03 from ¥1,300,673,202.35[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 47,191[6] - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of shares, totaling 330,941,729 shares[6] - The company has a total of 0 preferred shareholders at the end of the reporting period[7] Research and Development - Research and development expenses increased by 45.30% to ¥142,277,701.47 from ¥97,918,833.44 year-on-year[5] - Research and development expenses increased to CNY 142,277,701.47, compared to CNY 97,918,833.44, marking a year-over-year increase of 45.16%[12] Other Information - The report indicates that there are no significant new strategies or product developments mentioned in the current quarter[8] - The company reported a decrease in tax expenses to CNY 29,796,752.46 from CNY 42,198,139.45, a reduction of 29.36%[12] - Other comprehensive income after tax was CNY 14,776.38, compared to a loss of CNY 54,155.88 in the previous year, indicating a positive turnaround[14] - The company did not conduct an audit for the Q1 2022 report[18]

Financial Performance - The total revenue for 2021 was ¥8,942,618,232.82, representing a 13.49% increase compared to ¥7,879,672,743.47 in 2020[11]. - The net profit attributable to shareholders was ¥955,550,170.21, up 17.00% from ¥816,730,067.12 in the previous year[11]. - The net profit after deducting non-recurring gains and losses was ¥833,083,068.11, reflecting a 20.53% increase from ¥691,196,908.38 in 2020[11]. - The basic earnings per share for 2021 was ¥0.8108, a 17.00% increase compared to ¥0.6930 in 2020[11]. - The total revenue for the first quarter was ¥1,966,705,576.05, with a peak in the fourth quarter at ¥2,543,464,846.12, reflecting a quarterly growth of approximately 29%[14]. - Net profit attributable to shareholders in the second quarter reached ¥336,250,963.73, while the fourth quarter saw a decline to ¥193,416,570.79, indicating a year-over-year decrease of about 43%[14]. - The company achieved a gross profit of CNY 125,327.10 million, with a gross margin of 19.15%[28]. - The CDMO business generated revenue of CNY 139,392.68 million, a year-on-year increase of 32.09%, with a gross profit of CNY 60,108.73 million and a gross margin of CNY 43.12%[28]. - The company's formulation business reported revenue of CNY 86,743.45 million, a 14.11% increase year-on-year, with a gross profit of CNY 49,810.79 million and a gross margin of 57.42%[28]. Assets and Liabilities - The total assets at the end of 2021 amounted to ¥9,163,329,850.05, a 22.26% increase from ¥7,494,787,957.34 at the end of 2020[11]. - The net assets attributable to shareholders were ¥5,060,005,493.00, which is a 15.24% increase from ¥4,390,675,233.32 in 2020[12]. - The company's total liabilities reached ¥4,103,324,357.05, up from ¥3,104,112,724.02, marking a growth of around 32.2%[167]. - The total equity attributable to shareholders increased to ¥5,060,005,493.00 from ¥4,390,675,233.32, showing a rise of about 15.2%[168]. - Accounts receivable amounted to ¥1,446,516,969.93, representing 15.79% of total assets, an increase of 1.33% from the previous year[48]. - The company's total liabilities were ¥363,483,300.68 in 2021, an increase from ¥292,812,732.79 in 2020, reflecting a rise of 24.1%[171]. Cash Flow - The net cash flow from operating activities was ¥611,748,728.68, down 42.26% from ¥1,059,526,132.55 in 2020[11]. - The net cash flow from investment activities dropped significantly by 584.55%, resulting in a net outflow of ¥515,391,145.01 in 2021[46]. - The cash and cash equivalents at the end of the reporting period were ¥2,610,010,623.44, accounting for 28.48% of total assets, a slight decrease of 0.80% from the previous year[48]. - The cash flow from financing activities resulted in a net outflow of approximately ¥204.32 million in 2021, contrasting with a net inflow of approximately ¥78.75 million in 2020[180]. Research and Development - The company invested a total of 479 million CNY in R&D in 2021, representing a year-on-year increase of 34.88% and accounting for 5.36% of total revenue[22]. - The company submitted 14 invention patent applications and received 13 invention patent authorizations during the reporting period, with a total of 131 valid patents by the end of the period[22]. - The company has a total of 879 R&D personnel, including 46 PhDs and 192 Masters, emphasizing its commitment to innovation-driven development[25]. - Research and development expenses increased by 27.47% to 446,219,087.77 CNY in 2021, compared to 350,055,448.09 CNY in 2020[39]. Market and Industry Position - The pharmaceutical manufacturing industry is undergoing significant reforms, with an average price reduction of 53% in selected drugs due to centralized procurement initiatives[19]. - The company has achieved notable rankings, including 40th in the "Top 100 Pharmaceutical Enterprises" by the Ministry of Industry and Information Technology in 2020[21]. - The company has established strategic partnerships with over 30 domestic innovative drug companies to enhance its CDMO business[28]. - The company has a global marketing network covering over 70 countries and regions, with a strong presence in North America, Europe, and Asia[25]. Governance and Compliance - The company maintains independence from its controlling shareholders in terms of assets, personnel, and financial operations[62]. - The internal audit department conducted an audit focusing on high-risk areas, providing preventive corrective measures based on findings[60]. - The company emphasizes compliance and governance through its board structure and independent directors[68]. - The company has not faced any major litigation or arbitration matters during the reporting period[124]. Environmental Responsibility - The company is classified as a key pollutant discharge unit, with total COD emissions of 285.19 tons, well below the regulatory limit of 500 mg/L[107]. - The company has implemented a self-inspection and correction process in accordance with the "Special Action Checklist for Listed Company Governance" to enhance governance practices[106]. - The company has invested approximately CNY 37.52 million to enhance wastewater pollution prevention capabilities, ensuring stable and compliant discharge of wastewater[109]. - The company has implemented a "zero direct discharge" transformation for wastewater, actively promoting rainwater and sewage diversion[109]. Shareholder Information - The company plans to distribute a cash dividend of ¥2.85 per 10 shares, based on a total of 1,178,523,492 shares[1]. - The company distributed cash dividends amounting to 35% of the distributable profits in recent years, ensuring shareholder returns[118]. - The total number of shares for the company is 1,178,523,492, with 99.99% being unrestricted shares[139]. - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of the shares, totaling 330,941,729 shares, which are pledged[140].

Financial Performance - The company's revenue for Q3 2021 reached ¥2,122,027,692.91, representing a 16.67% increase year-over-year[2] - Net profit attributable to shareholders was ¥208,725,104.95, up 4.03% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses was ¥169,749,985.78, reflecting a 9.82% increase year-over-year[2] - The company reported a 22.45% increase in operating profit, totaling ¥903,070,746.23, driven by higher sales and gross profit[6] - Total operating revenue for Q3 2021 reached CNY 6,399,153,386.70, an increase of 10.1% compared to CNY 5,810,594,633.35 in the same period last year[13] - Net profit attributable to the parent company was CNY 762,133,599.42, up from CNY 630,118,433.62, representing a growth of 20.9% year-over-year[14] - Operating profit for the period was CNY 903,070,746.23, compared to CNY 737,500,990.95 in the previous year, indicating a rise of 22.5%[13] - Total operating costs for the period were CNY 5,585,830,987.06, compared to CNY 5,195,242,655.36, indicating an increase of 7.5%[13] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥8,786,552,584.33, a 17.24% increase from the previous year[2] - The equity attributable to shareholders increased to ¥4,866,465,554.98, marking a 10.84% rise compared to the end of the previous year[2] - Total liabilities rose to CNY 3,920,087,029.35, up from CNY 3,104,112,724.02, representing a growth of 26.3%[12] - The company's total current assets as of September 30, 2021, amounted to ¥5,827,751,885.92, an increase from ¥4,917,396,988.87 in the previous year[11] - The total non-current assets increased to ¥2,958,800,698.41 from ¥2,577,390,968.47 year-over-year[11] Cash Flow - The operating cash flow for the year-to-date was ¥660,960,893.14, showing a significant decline of 33.83% year-over-year[2] - The net cash flow from operating activities for Q3 2021 was ¥660,960,893.14, a decrease of 33.9% compared to ¥998,942,728.52 in Q3 2020[16] - Total cash inflow from operating activities amounted to ¥5,029,206,843.86, up 12.4% from ¥4,472,455,219.77 in the same period last year[16] - Cash outflow from operating activities increased to ¥4,368,245,950.72, representing a rise of 25.7% compared to ¥3,473,512,491.25 in Q3 2020[16] - The net cash flow from investing activities was -¥452,030,530.24, a significant decline from ¥186,031,436.43 in Q3 2020[16] - Cash inflow from investing activities totaled ¥169,243,259.74, down 70.7% from ¥576,541,842.14 in the previous year[16] - Cash outflow from investing activities increased to ¥621,273,789.98, up 59.1% from ¥390,510,405.71 in Q3 2020[16] - The net cash flow from financing activities was -¥153,091,066.39, compared to -¥26,791,420.46 in Q3 2020[17] - Cash inflow from financing activities reached ¥785,100,000.00, a substantial increase from ¥230,100,000.00 in the same quarter last year[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 25,248[8] - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of shares, totaling 330,941,729 shares, with 156,000,000 shares pledged[8] - The company has a total of 32,664,016 shares held under the first employee stock ownership plan[9] Research and Development - Research and development expenses increased by 18.12% to ¥321,495,631.04, indicating a focus on innovation[6] - Research and development expenses increased to CNY 321,495,631.04, up from CNY 272,178,180.32, reflecting a growth of 18.1%[13] Inventory and Accounts Payable - Inventory increased to ¥1,146,406,041.90 from ¥1,086,181,605.07 in the previous year[11] - The company reported a total of ¥1,341,874,527.90 in accounts payable, compared to ¥682,462,979.39 in the previous year[11] Audit Information - The company did not undergo an audit for the Q3 2021 report[18]

Financial Performance - The company's operating revenue for the reporting period was ¥4,277,125,693.79, representing a 7.15% increase compared to ¥3,991,768,060.82 in the same period last year[12]. - The net profit attributable to shareholders of the listed company was ¥553,408,494.47, which is a 28.86% increase from ¥429,471,282.68 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥503,398,008.59, up 25.43% from ¥401,338,011.97 in the same period last year[12]. - The basic earnings per share for the reporting period was ¥0.4696, reflecting a 28.87% increase compared to ¥0.3644 in the previous year[12]. - The total assets at the end of the reporting period were ¥8,435,811,838.42, which is a 12.56% increase from ¥7,494,787,957.34 at the end of the previous year[12]. - The net assets attributable to shareholders of the listed company were ¥4,657,745,885.88, representing a 6.08% increase from ¥4,390,675,233.32 at the end of the previous year[12]. - The net cash flow from operating activities was ¥323,169,178.27, showing a decrease of 49.90% compared to ¥645,027,102.57 in the same period last year[12]. - The weighted average return on net assets was 12.10%, an increase of 1.23% from 10.87% in the previous year[12]. Business Segments - The CDMO business generated revenue of 720.82 million yuan, up 30.65% year-on-year, with a gross margin of 43.32%, an increase of 2.55 percentage points[17]. - The total number of CDMO clients increased by 51.0% year-on-year, with 355 quoted projects, a 157% increase, and 250 ongoing projects, a 71% increase[17]. - The raw material intermediate business reported revenue of 3.137 billion yuan, a growth of 3.90% year-on-year, with a gross margin of 23.02%[18]. - The formulation business achieved revenue of 402.19 million yuan, a year-on-year increase of 9.46%, with a gross margin of 64.60%, up 10.65 percentage points[19]. Strategic Initiatives - The company is focusing on strategic goals of "refining raw materials, strengthening CDMO, and optimizing formulations" to navigate the complex external environment[17]. - The company is actively expanding its product pipeline, with several new products approved and entering the market, including the injection of cefoperazone[19]. - The company plans to increase its CDMO R&D investment, with a goal of expanding its Shanghai R&D center from 130 to 500 personnel by 2024[24]. - The company is adapting to regulatory changes and increasing environmental standards, which are impacting the pharmaceutical industry[19]. Market Overview - The global pharmaceutical market size is expected to reach $1.45 trillion in 2021 and $1.6395 trillion by 2024, with a compound annual growth rate (CAGR) of 4.4% from 2019 to 2024[20]. - China's pharmaceutical industry has become a major global player, with raw material drug exports accounting for approximately 20% of the global market share[21]. - The CDMO industry in China reached over 40 billion yuan in 2019, growing at approximately 19%, significantly outpacing the global CDMO market growth rate of about 13%[23]. Research and Development - The company has completed 4 domestic formulation registrations and 2 API registrations during the reporting period, along with 7 new DMF submissions for raw materials[25]. - The company has a total of 745 R&D personnel, including 144 with master's degrees and 45 with doctoral degrees[24]. - The global pipeline of new drugs reached 16,000 in 2019, reflecting a year-on-year growth of approximately 6%, supporting the rapid development of the CDMO business[22]. - The company has submitted 7 invention patent applications and received 5 invention patent grants in the first half of the year, with a total of 123 effective patents by the end of the reporting period[25]. Environmental and Social Responsibility - The company has invested in 12 sets of RTO waste gas treatment facilities, achieving a total organic waste gas treatment capacity of 350,000 m³/h[28]. - The company has implemented a three-year action plan for EHS, focusing on VOCs governance and ensuring the normal operation of pollution prevention facilities[28]. - The company has established a comprehensive emergency response plan for safety and environmental incidents, with all subsidiaries having set up EHS management organizations[58]. - The company has actively engaged in social responsibility initiatives, including charity activities and support for employees in need[62]. Financial Management - The company's financial expenses increased significantly by 356.11% due to exchange losses, compared to a gain in the previous year[32]. - The company aims to become a leading technology-driven pharmaceutical manufacturer in China, supported by its "344" quality management model[31]. - The company has established a global marketing network covering over 70 countries and regions, with a strong presence in North America, Europe, and Asia[31]. - The company has passed multiple international certifications, including WHO, FDA, and EU EDQM, enhancing its credibility in the global market[31]. Shareholder Information - The total share capital as of the last trading day before disclosure was 1,178,523,492 shares[12]. - The company has implemented an employee stock ownership plan, acquiring 32,664,016 shares, which represents 2.77% of the total share capital, for a total transaction amount of ¥260,658,847.68[49]. - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of the shares, amounting to 330,941,729 shares[90]. Compliance and Governance - The company adheres to the accounting standards set by the Ministry of Finance and the China Securities Regulatory Commission, ensuring the financial statements reflect true and complete financial conditions[138]. - The company has no significant doubts regarding its ability to continue as a going concern for the next 12 months[136]. - The company has not faced any administrative penalties for environmental issues during the reporting period[59]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[65].

普洛药业股份有限公司 2021 年第一季度报告全文 普洛药业股份有限公司 2021 年第一季度报告 2021 年 04 月 1 普洛药业股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人祝方猛、主管会计工作负责人张进辉及会计机构负责人(会计主 管人员)张进辉声明：保证季度报告中财务报表的真实、准确、完整。 2 普洛药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|-----------------------------|-----------------------------|-------------------------------| ...

Financial Performance - The company's operating revenue for 2020 was ¥7,879,672,743.47, representing a 9.28% increase from ¥7,210,711,386.14 in 2019[10] - The net profit attributable to shareholders for 2020 was ¥816,730,067.12, a 47.58% increase compared to ¥553,400,761.42 in 2019[10] - The basic earnings per share for 2020 was ¥0.6930, up 47.57% from ¥0.4696 in 2019[10] - The total operating revenue for 2020 was approximately ¥7.88 billion, representing a year-on-year increase of 9.28% from ¥7.21 billion in 2019[30] - The pharmaceutical main business revenue was approximately ¥7.85 billion, accounting for 99.64% of total revenue, with a year-on-year increase of 9.08%[30] - The total operating profit for 2020 was approximately ¥969.71 million, an increase of 50.6% compared to ¥644.15 million in 2019[162] - The comprehensive income total for 2020 was approximately ¥817.14 million, compared to ¥553.34 million in 2019, reflecting a significant growth[163] - The total profit for 2020 was approximately ¥961.15 million, an increase of 51.6% compared to ¥633.73 million in 2019[162] Assets and Liabilities - The total assets at the end of 2020 were ¥7,494,787,957.34, reflecting a 14.91% increase from ¥6,522,585,923.42 at the end of 2019[10] - The total liabilities of Pro Pharmaceutical Co., Ltd. increased to CNY 3,104,112,724.02 from CNY 2,754,599,136.14, marking a rise of around 12.7%[155] - The company's equity attributable to shareholders rose to CNY 4,390,675,233.32, compared to CNY 3,767,986,787.28 in 2019, reflecting an increase of approximately 16.5%[156] - The total current liabilities increased to CNY 2,896,461,565.37 from CNY 2,561,555,217.89, reflecting a growth of approximately 13.1%[155] Cash Flow - The net cash flow from operating activities for 2020 was ¥1,059,526,132.55, a decrease of 22.10% from ¥1,360,066,190.36 in 2019[10] - The company reported a net increase in cash and cash equivalents of CNY 1,206,365,433.90, compared to CNY 216,352,891.90 in 2019, indicating a substantial improvement[169] - The total cash and cash equivalents at the end of 2020 reached CNY 1,924,438,773.93, up from CNY 718,073,340.03 at the end of 2019[169] Research and Development - The company expanded its R&D team by hiring 89 new technical personnel, including 35 with doctoral or master's degrees, with total R&D investment reaching 355 million CNY, accounting for 4.51% of operating revenue[25] - The company plans to focus on research and development in biopharmaceutical technology and expand its market presence through strategic investments[192] - The company has established five career development paths, including management and research sequences, with corresponding assessment and incentive mechanisms[119] Market Position and Strategy - The company has established a strong market position in the pharmaceutical manufacturing industry, focusing on APIs, CDMO services, and formulation business[16] - The company has a global sales network covering over 70 countries and regions, with a significant export position in chemical APIs[21] - The company plans to continue focusing on its development strategy of refining raw materials, strengthening CDMO, and optimizing formulations, while enhancing R&D innovation and operational efficiency[50] Compliance and Governance - The company has maintained compliance with its commitments regarding independence and avoidance of competition, as stated in its long-term commitments[57] - There were no significant accounting errors or restatements during the reporting period, ensuring the integrity of the financial statements[59] - The company has engaged an independent auditor to assess the effectiveness of its internal controls, ensuring compliance with regulatory standards[123] Environmental Responsibility - The company invested approximately 81.88 million CNY in 2020 to enhance wastewater treatment capabilities and reduce total water pollutant emissions[89] - The company has implemented various pollution control measures, ensuring emissions are within regulatory limits[87] - The company is actively engaged in comprehensive air pollution control efforts as per national guidelines, focusing on volatile organic compounds[92] Shareholder Information - The company plans to distribute a cash dividend of ¥2.43 per 10 shares based on a total share capital of 1,178,523,492 shares as of December 31, 2020[2] - The company reported a cash dividend of ¥286,381,208.56 for the year 2020, which is 35.06% of the net profit attributable to ordinary shareholders[54] - The total distributable profit for the period was 300,416,376.58 CNY, indicating a strong commitment to returning value to shareholders[56] Employee and Management Changes - The company appointed Xu Xinliang as General Manager and Jin Min as Senior Vice President on January 2, 2020[109] - The company reported a significant management change with the dismissal of Zhu Fangmeng as General Manager due to work reasons on January 2, 2020[109] - The company has a diverse management team with members holding advanced degrees and extensive experience in various sectors, including pharmaceuticals and finance[110]